SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop ($GME) is trending amid discussions of a potential meme stock rally, fueled by a recent White House post referencing their slogan, "Power to the Players." The community is debating the significance of this endorsement, drawing comparisons to past events and potential short squeezes, while some caution against hype and dilution.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies behind its vision, touting it as 'like Bitcoin but way higher.' Discussions are centered around its potential within the Solana ecosystem and its mission to champion cannabis as natural medicine, advocating for its widespread acceptance.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as community members rally around the narrative of honoring Satoshi Nakamoto, viewing the token as a representation of the entire crypto industry. Discussions highlight the token's potential for significant growth and its strong community, with many considering it the 'Bitcoin of memes'. The conversation emphasizes the token's long-term relevance and the growing movement behind it.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The DIA is trending amid U.S.-China trade tensions and fluctuating market sentiment, with community members closely monitoring economic data and potential Federal Reserve actions. Discussions include concerns about specific sectors like regional banks and the potential impact of tariffs on consumer prices. Some traders express skepticism about market fundamentals, while others see opportunities in specific stocks or strategies.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Global X Dow 30 Covered Call ETF ($DJIA) is trending as the market anticipates potential interest rate cuts from major central banks, which could influence global liquidity and market sentiment. Community members are actively discussing potential options strategies, specifically LEAPS, to capitalize on possible market movements. Some users are also expressing strong opinions and frustrations unrelated to market analysis.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending as investors discuss potential real estate tokenization and a possible partnership with Robinhood ($HOOD). Bullish sentiment is fueled by anticipation of positive catalysts like potential rate cuts and upcoming earnings, with some traders drawing comparisons to past meme stock rallies. Community members are speculating on price targets and debating the company's long-term prospects amid discussions of its AI-driven approach to the real estate market.

Pump.fun

$PUMP is trending as the community rallies around the 'We're All Gonna Make It' ($WAGMI) narrative, emphasizing long-term community building and support within the Solana ecosystem. Discussions highlight the token's resilience and the strong conviction of its holders, who are focused on building a lasting presence in the meme coin space. The community is actively promoting the project's mission and encouraging others to join their movement.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as community members discuss its potential in AI and data centers, drawing comparisons to other high-growth stocks. Bullish sentiment revolves around potential revenue from GPU capacity and possible partnerships, with some suggesting ambitious price targets. However, the stock has seen volatility, leading to discussions around short positions and potential pullbacks.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol ($VIRTUAL) is trending due to recent positive price action, with community members expressing excitement and discussing potential gains. The crypto's ecosystem of AI agents seems to be attracting attention, with some suggesting a broader altcoin rally may be underway. Community members are also actively discussing Virtual Protocol's integration with the Base network.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as traders discuss technical analysis, highlighting bullish patterns and potential price targets, with some focusing on swing trading opportunities using Elliott Wave analysis. Upcoming earnings are a key catalyst mentioned, with community members anticipating strong results, particularly from Azure and Copilot, while others discuss the potential impact of AI-related news and partnerships on the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus 

Shares of Immunovant, Inc. (IMVT) traded 2% higher on Thursday morning after the company reported a narrower-than-expected first-quarter loss.The clinical-stage immunology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial">reported</a> a net loss of $0.64 per share for the quarter compared to a loss of $0.52 for the corresponding quarter of 2024, and lower than an estimated loss of $0.72 per share, as per Finchat data.The company’s increased research and development expenses, as well as general and administrative expenses, weighed on its bottom line, with the net loss widening to $106.45 million.Immunovant is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.Its candidate IMVT-1402 is being developed for the treatment of multiple illnesses, including Graves’ disease (GD), difficult-to-treat Rheumatoid Arthritis (D2T RA), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Sjögren’s Disease (SjD).The company ended the quarter with cash and cash equivalents totalling approximately $714 million, expected to provide runway till 2027.Last month, Immunovant announced changes to its leadership as part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.The company appointed Eric Venker as CEO, replacing Pete Salzmann, and Tiago Girao as CFO, replacing Renee Barnett.On Stocktwits, retail sentiment around IMVT stayed within the ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_10_09_02_AM_png_50dfeaa22a.webp" alt="IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> According to data from Koyfin, 12 of the 15 analysts covering Immunovant rate it a ‘Buy’ or higher, while three rate it a ‘Hold’. The stock has an average price target of $45.15, representing an upside of over 200% from its current share price.<a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by about 43% this year and by about 51% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/iridium-partners-with-syniverse-to-launch-global-satellite-service/ch0AYoSRbto">Iridium Partners With Syniverse To Launch Global Satellite Service: Retail Stays Confident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.

Equity

Immunovant, Inc. (IMVT) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant">announced</a> on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, following Salzmann's retirement from his role.Venker, meanwhile, will continue to serve on Immunovant’s Board of Directors.Tiago Girao will be the company’s new CFO, replacing Renee Barnett. Girao was formerly the CFO of biopharmaceutical company Telavant Holdings.Immunovant stated that these changes are part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.&nbsp; George Migausky has stepped down from the Immunovant board of directors, and Robert Susman and Jacob Bauer have joined the board, effective April 18, 2025, the company added.Immunovant is a clinical-stage immunology company developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.The company now plans to study its IMVT-1402, an anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases, in the treatment of Sjögren’s disease and Cutaneous Lupus Erythematosus as well. No therapies have been explicitly approved for the treatment of Sjögren’s disease to date, it said.The company said it is beginning to conclude development activities for batoclimab, an anti-FcRn monoclonal antibody.Venker said that Immunovant has shown “compelling efficacy data” in clinical trials for batoclimab in Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease, and Thyroid Eye Disease.Immunovant said that its current cash balance is expected to provide a runway till 2027.On Stocktwits, retail sentiment around the stock jumped from ‘bearish’ to ‘bullish’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:644/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_21_at_8_09_32_AM_png_03ceffe093.webp" alt="IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits" width="644" height="147"><figcaption>IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by over 40% so far this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-as-trump-tariffs-cloud-earnings-season/chQiK8CRbQg">Dow Futures Decline As Trump’s Tariffs Cloud Earnings Season: Tech Bull Says ‘White House Needs Trade Deals Done Quick’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24...

What the Options Market Tells Us About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Immunovant Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$18.94
Prev Close	$18.74
Open	$18.83
Dividend Yield	0.00%
50-Day Moving Average	$16.28
Beta	0.99
Avg. Volume	1.99M
PE Ratio	-6.66

52-Week High	$32.10
52-Week Low	$12.72
Market Capitalization	$3.3B
EPS (Annual)	-$2.73
Price to Book	5.32
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMVT
Immunovant Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMVT News

IMVTImmunovant Inc